They are India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report. They operate an integrated, end-to-end business that aims to provide solutions for healthcare needs of consumers across the following critical stages
A. providing digital tools and information on illness and wellness,
B. offering teleconsultation,
C. offering diagnostics and radiology tests, and
D. delivering treatment protocols including products and devices.
Their custom-built proprietary technology, unified data platforms, supply chain capabilities, and deep understanding of the dynamic interplay between the various sub-segments of India’s healthcare market are the capabilities that differentiate us.
These capabilities enable them to provide each stakeholder in the healthcare value-chain, viz.:
(a) channel (wholesalers, retailers and chemists / institutions),
(b) consultants (and hospitals), diagnostic and radiology labs,
(c) consumers, and
(d) companies (pharmaceutical, nutraceutical, medical devices)
with the technology tools and capabilities to solve their challenges, while also enabling them to benefit from an interconnected network. At the same time, they also enable them to build a scaled presence, allowing their platform to reach a wide base of stakeholders across the length and breadth of this country. Their businesses have a presence across the country, with last-mile 163 capabilities to deliver in over 18,587 pin codes (for June 2021) via PharmEasy marketplace, allowing them the ability to provide access in an affordable manner to the common man. Their platforms have scaled across urban, semi-urban and rural India, with an ability to serve people across income groups and geographies.
Source: PharmEasy IPO DRHP
Source: PharmEasy IPO DRHP
Source: PharmEasy IPO DRHP
Pharmeasy:
PharmEasy is a consumer healthcare “super app”.
PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
25 Million+Total Users
8.8 million+Total Orders
2.4 million+Transacting Customers
Services:
Order Medicines
Healthcare Products
Diagnostic Tests
Source: PharmEasy IPO DRHP
Name | API Holdings Limited Unlisted Shares |
---|---|
Alias Name | PharmEasy |
Face Value | ₹ 1 |
ISIN Code | INE0DJ201029 |
Unlisted Share Price | ₹ 47 Per Share |
Lot Size | 500 Shares |
PAN | AASCA1201E |
Particulars | 2019-20 | 2020-21 |
---|---|---|
Revenues from Operations | 6675.42 | 23352.69 |
Total Income | 7374.48 | 23606.62 |
Total Expenses | 10844.04 | 29809.28 |
Profit/(Loss) before tax | (3469.56) | (6202.66) |
Profit/(Loss) after tax for the period | (3352.79) | (6413.36) |
*Rates mentioned in the chart are indicative.
Total Number of Outstanding Shares: 6,098,109,930 (As per PharmEasy IPO DRHP)
Market Cap Scenarios:
At 45 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs. 27,400 crores.
This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.
At 50 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs. 30,490 crores.
This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.
At 55 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs. 33,540 crores.
This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.
At 60 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs.36,590 crores.
This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.
Source: PharmEasy IPO DRHP
Other Shareholders includes key shareholders & public
The minimum lot size for investing in PharmEasy Unlisted Shares is 200 Shares
The Lock-in period for PharmEasy Unlisted Shares will be Six Months. The Lock-in period starts from the date of IPO allotment.(According to DRHP)
Yes, buying PharmEasy Unlisted Shares is completely legal.
You can regularly check the updated price of PharmEasy Unlisted Shares at our Website and on our Telegram Channel
The IPO of PharmEasy (API Holdings Limited) can be expected in very short term. The company has already filed its DRHP with SEBI.
Get best quotes prevailing in the market
Get shares in your demat in few hours only!
Hassle-free payments through NEFT, IMPS & UPI
120-B, Behind Vaishali Enclave, Anjar-Kutch, Gujarat
Copyright 2022 @ Unlisted Arena. All rights reserved.